Análisis Argos
DGX
DGXEn su precio
Quest Diagnostics Incorporated · Healthcare
US$ 215.72
precio al 2026-07-04
Valor justo Argos*
US$ 166–185
vs. su valor justo
18% por encima
Score Argos
58/100
En su precio
LA RESPUESTA
El precio asume un crecimiento (11.3%) en línea con lo que la empresa demuestra (5.3%). Ni ganga ni exceso — el mercado le puso un precio razonable.
Recompensas
Cotiza 11% por debajo de su valor justo.
Las ganancias crecieron 14% el último año.
Riesgos
!Crecimiento estancado o en baja.
VALOR3/6FUTURO2/6PASADO3/6SALUD3/6DIVIDENDO4/6
El Iris de calidad
VALOR3/6FUTURO2/6PASADO3/6SALUD3/6DIVIDENDO4/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos58de 100En su precio
Ingresos12%
US$ 11 B
Margen operativo7%
14.5%
Flujo de caja libre49%
US$ 1.4 B
Deuda neta
US$ 6.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 23.9B
P/E24.1x
EV/EBITDA14x
FCF yield5.7%
ROIC9%
Margen operativo14.5%
Crecim. ingresos+11.8%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 2 jul
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com · 25 jun
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
gurufocus.com · 24 jun
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100
On June 24, 2026, Quest Diagnostics Inc (DGX) shares rose 3.0% today, currently trading at $203.11. This performance places the stock well within its 52-week ra
prnewswire.com · 24 jun
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
zacks.com · 23 jun
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.
zacks.com · 19 jun
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com · 18 jun
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
prnewswire.com · 18 jun
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the three most used oral antibiotics SECAUCUS, N.J., June 18, 2026 /PRNewswire/ -- A common bacterial strain that lives naturally in people's guts can cause a dangerous or deadly infection for some, especially when it becomes multidrug-resistant and causes chronic urinary-tract infections (UTIs) in elderly women.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.